

# Development of TMAU Treatment through FDA Rare Disease Designation and IND Approval



METABOLIC	Preclinical
Product Type	A microbiome strain (BM109)
Indication	Trimethylaminuria (TMAU), expandable to cardiovascular and chronic kidney disease
Target	Decomposition of trimethylamine (TMA) by BM 109
MoA(Mechanism of Action)	Breaking down trimethylamine by 12 enzymes (TMA monooxygenase, reductase, demethylase, dehydrogenase, N-Methylglutamate synthase, etc) produced by a microbiome strain (BM 109)
Competitiveness	<p>While there is no direct competition, several solutions can help ease and/or relieve the disease:</p> <p><b>Dietary Changes:</b> Implementing a low choline diet and avoiding trigger foods.</p> <p><b>Medications:</b> Utilizing antibiotics, activated charcoal, and copper chlorophyllin.</p> <p><b>Personal Hygiene:</b> Maintaining rigorous personal hygiene practices.</p> <p><b>Stress Management:</b> Employing effective stress management techniques.</p>
Development Stage	Preclinical
Route of Administration	Oral capsule